Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2837525

Cc1ccc(C(CC(=O)O)Cc2nc(CCCc3ccc4c(n3)NCCC4)no2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 20/20 0.79
ITGAV P06756 20/20 0.79
ITGA2B P08514 19/20 0.79
ITGB6 P18564 9/20 0.71
ITGB5 P18084 6/20 0.71
ITGB1 P05556 3/20 0.70
ITGB8 P26012 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5856799 0.93 ITGB3 (0.80) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL5859342 0.93 ITGB3 (0.91) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2842123 0.93 ITGAV (0.79) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2842923 0.92 ITGB3 (0.75) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL5858263 0.92 ITGB3 (0.75) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2838415 0.91 ITGB3 (0.74) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2838652 0.91 ITGB3 (0.75) ITGB3ITGAVITGA2BITGB6ITGB5
SCHEMBL8337741 0.90 ITGAV (0.82) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2837343 0.90 ITGB3 (0.79) ITGB3ITGAVITGA2BITGB6ITGB5
Trifluoroacetic Acid SCHEMBL2834556 0.90 ITGB3 (0.81) ITGB3ITGAVITGA2BITGB6ITGB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592421-A1 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS Pharmacia Corporation (US) 2005-11-09 EP claimed
US-20050043344-A1 Heteroarylalkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2005-02-24 US claimed
WO-2004058254-A1 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS PHARMACIA CORPORATION (US) 2004-07-15 WO claimed
US-9345739-B2 Methods and compositions for the treatment of proteinuric diseases THE GENERAL HOSPITAL CORPORATION (US) 2016-05-24 US disclosed
US-20100297139-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES THE GENERAL HOSPITAL CORPORATION 2010-11-25 US disclosed
EP-1592421-A1 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS Pharmacia Corporation (US) 2005-11-09 EP disclosed
US-20050043344-A1 Heteroarylalkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2005-02-24 US disclosed
WO-2004058254-A1 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS PHARMACIA CORPORATION (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043344-A1 Heteroarylalkanoic acids as integrin receptor antagonists derivatives ITGA5, ITGAV, ITGA6 ITGB3 6/4885ITGAV 2/4885ITGA2B 8/4885
US-20100297139-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES ITGB3, PLAUR, PROC ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.